

## Prior Authorization Workflow-to-Standards Task Group Update

Tony Schueth Task Group Leader

National Committee on Vital and Health Statistics Subcommittee on Standards & Security

December 7, 2005



# Task Group Overview

- Task Group Name:
  - Prior Authorization Workflow-to-Transactions
- Date Task Group Formed:
  - November 18, 2004
- Task Group Leader:
  - Tony Schueth, MS
- Objectives:
  - Identify the standards required to support ePrescribing the electronic delivery of PA-related transactions
  - Understand PA work flow in the physician office, plan and pharmacy



### Philosophy

"... this is not an attempt to usurp the coverage decisions of the plans but an effort to streamline and standardize the mechanism for the activity."

> - NCPDP Prior Authorization Workflow-to-Transactions Task Group Member



## **Task Group Members**

Name	Company		
Alan Smith	ProxyMed		
Andy Fontalbert	ACS		
Avi Erlich	Wellpoint		
Barbara McKinnon	Point-of-Care Partners		
Barbara Hollerung	MN Medicaid		
Brandon Brylawski, MD	DrFirst		
Brian Bamberger	MediMedia		
Carolyn Gingras, MS	Lifespan		
Cody Wibert	State of Minn.		
Colin Halloran	Express Scripts		
Dan Makowski, RPh	Allscripts		
Darlene Rocco, RPh	Excellus		
Jeff Mays	MediMedia		
John Klimek, RPh	Albertsons		
Kathy Finley	Argus		
Keith Faigin	EHIM		
Lynne Gilbertson	NCPDP		
Margaret Weiker	EDS		
Mark Gruenhaupt	Argus		

Name	Company			
Michael Van Orum, RN, ,RPH	American Home Patient			
Nancy Nemes	WebMD			
Ned Hanson	HealthNet			
Peter Kaufman, MD	DrFirst			
Shelly Spiro, RPh	Consultant			
Reid Coleman, MD	Lifespan			
Richard Stefanicci	USIP			
Rohit Nayak	MedPlus			
Ross Martin, MD	Pfizer			
Sandra Ebel	X12			
Sherry Neuman	Consultant			
Spencer Rylander	Lifespan			
Stacey Barber	EDS, X12			
Steve Waldren, MD	AAFP			
Stuart Kersky, RPh	Walgreens			
Sue Thompson	West VA Medicaid, HL7			
Terry Torgler	Argus			
Teri Byrne	RxHub			
Tim McNeil	RxHub 4			



### Definitions

- Status a designation indicating whether a medication requires prior authorization
- Criteria systematically developed statements that can be used to assess appropriateness.
- *Rule* code or set of codes governing action or procedure.



# Sample PA Form - Celebrex



CONTAINS CONFIDENTIAL PATIENT INFORMATION Celebrex (celecoxib) Prior Authorization of Benefits (PAB) Form

Complete form in its entirety and fax to: Prior Authorization of Benefits (PAB) Center at (888) 831-2243

#### 1. PATIENT INFORMATION

#### 2. PHYSICIAN INFORMATION

Patient Name:	Prescribing Physician:
Patient ID #:	Physician Specialty:
Patient DOB:	Physician DEA#:
Date of Rx:	Physician Phone#:
Patient is: 🛛 Female 🗳 Male	Physician Fax#:

#### 3. INDICATE DIAGNOSIS

Diagnosis:	th: Celebrex 200mg Celebrex I 100mg Celebrex 200mg Celebrex 400mg Celebrex 400mg Celebrex 400mg 60 per 30 days 0 200mg 11 per 30 days 60 per 30 days				
Strength:	Celebrex 200mg	1			Familial Adenomatous Polyposis Celebrex 400mg
Max Qty Limit:	30 per 30 days	60 per 30 days 📮 2	200mg		0
	OA or RA: Must meet criteria below in			Must be female and meet criteria	Only diagnosis required
	4A <u>OR </u> 4B <u>OR</u> 4C			below in 4A <u>OR</u> both 4B <u>AND</u> 4C	



### Sample PA – Celebrex cont.


#### 4. APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY

Any areas that are not filled out will be considered not applicable to your patient AND MAY AFFECT THE OUTCOME OF THIS REQUEST

A. 🗆	Yes		No	Patient has major NSAID-induced GI complication risk factors: ONE OF THE FOLLOWING MUST BE PRESENT
	Yes		No	Active non-menstrual bleeding or bleeding disorder
	Yes		No	Concurrent anticoagulation therapy Please note: bleeding events and increased prothrombin time have been reported in
				patients taking COX-II Selective NSAIDs concurrently with warfarin. INR monitoring is still necessary in COX-IIs.
	Yes		No	Patient has previous documented history of NSAID-induced gastropathy
в. 🗆	Yes		No	Patient has other NSAID-induced GI complication risk factors: TWO OR MORE OF THE FOLLOWING MUST BE PRESENT
	Yes		No	Age $\geq 65$ years old
	Yes		No	Chronic major organ impairment (please specify) or active Rheumatoid Arthritis
	Yes		No	Concomitant chronic systemic corticosteroid therapy
	Yes		No	Chronic high-dose NSAID therapy (e.g. 2-3 times the standard dose to achieve therapeutic effect)
	Yes		No	Anti-platelet agents for vascular prophylaxis
-			No	Patient has documented trial and failure of 2 or more prescription-strength NSAIDs
С. 🗆	Yes	-	110	(Must specify trials below)
	Yes			
NSA				(Must specify trials below) NSAID #2:
NSA 5. PH	ID #1:	N SI	GNA	(Must specify trials below) NSAID #2: TURE
NSA 5. PH Prescri	ID #1:	N SI	GNA zed Sig	(Must specify trials below) NSAID #2: TURE
NSA 5. PH Prescri Prior Au medicat	ID #1: (SICIA Der or Au thorization ons are a TANT W ntial, the	N SI	GNA zed Sig mefits is riate for a ING: TI	(Must specify trials below)           NSAID #2:    FURE   nature  nature  not the practice of medicine or the substitute for the independent medical judgment of a treating physician, only a treating physician can determine what



### What is the proposed workflow? (Feasible for CMS eRx pilots)





# Task Group Accomplishments

- Mapped ambulatory PA workflow
- Leveraged AHRQ grant to complete analysis of PA forms
- Analyzed 350 forms / 1,750 questions / 53 payers
- Created database to support analysis of industry forms
- Leveraged additional AHRQ grant to normalize data in the following therapeutic categories:
  - Erectile Dysfunction
  - Growth Hormones

- AntiFungals
- NSAIDs/Cox2s

– PPIs

- Opoid Agonists

- Unspecified
- Formed separate task group to address PA in Longterm Care
- Mapped Long-term Care PA workflow



### Timeline

	2005			20	06		
	12/05	1/06	2/06	3/06	4/06	5/06	6/06
PHASE 1		Present PA Progress at HL7 Conference	Present PA Progress at X12N Conference			Present PA Progress at HL7 Conference	Present PA Progress at X12N Conference
	X12N 278 - 5010 "public comments" reconciled		X12N 278 - 5010 Vote to Publish	X12N Technical Assessment	Publish 5010 Guide Published		
	X12N 275-5010 Post for "public comment"	Review Imp Guide at 1/06 conference		Reconcile "public comments"			Reconcile "public comments" at 6/06 conference
	HL7 PA Attachment Post for "public comment"	Announce Ballot	Post for Ballot	Open Ballot"	Close Ballot	Reconcile "public comments" at 5/06 conference	
PHASE 2	Planning for analysis of add'l 11 PA criteria categories	Normalize additional PA criteria	Normalize additional PA criteria	Normalize additional PA criteria	Normalize additional PA criteria	Review impact of add'I PA criteria on standards	



## **Next Steps**

- HL7 ballot of the PA Attachment
- Pilot Test
- Complete PA data normalization for remaining 11 therapeutic categories (?)
- Long-term care needs to determine the impact of PA to them, and how to streamline their processes